Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
Calvin Cohen(Community Research Initiative), Brian P. Kearney(Gilead Sciences (United States)), Richard Elion(Gilead Sciences (United States)), David Shamblaw(Gilead Sciences (United States)), S. Ramanathan(Alagappa University), Bruce Rashbaum(Gilead Sciences (United States)), Steven L. Chuck(San Francisco General Hospital), Peter Ruane, Edwin DeJesus(Orlando Immunology Center), Kitty Yale(Gilead Sciences (United States)), David R. Warren(Gilead Sciences (United States)), Hui C. Liu(Gilead Sciences (United States))
Cited by 109
Related Papers
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882
Infections with<i>Cryptococcus neoformans</i>in the Acquired Immunodeficiency Syndrome
|New England Journal of Medicine|1989|801
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
|New England Journal of Medicine|2001|519